BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 282 filers reported holding BLUEBIRD BIO INC in Q4 2019. The put-call ratio across all filers is 0.80 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $4,596,000 | -47.6% | 100,000 | 0.0% | 0.19% | -42.8% |
| Q4 2019 | $8,775,000 | -4.4% | 100,000 | 0.0% | 0.34% | -7.9% |
| Q3 2019 | $9,182,000 | -27.8% | 100,000 | 0.0% | 0.37% | -28.4% |
| Q2 2019 | $12,720,000 | -19.2% | 100,000 | 0.0% | 0.51% | -19.9% |
| Q1 2019 | $15,733,000 | -42.3% | 100,000 | -63.6% | 0.64% | -36.4% |
| Q4 2018 | $27,280,000 | +6.8% | 275,000 | +57.1% | 1.01% | +51.9% |
| Q3 2018 | $25,550,000 | -26.0% | 175,000 | -20.5% | 0.66% | -9.4% |
| Q2 2018 | $34,530,000 | +34.8% | 220,000 | +46.7% | 0.73% | +128.7% |
| Q1 2018 | $25,613,000 | -28.1% | 150,000 | -25.0% | 0.32% | -40.2% |
| Q4 2017 | $35,620,000 | +40.2% | 200,000 | +8.1% | 0.54% | +22.9% |
| Q3 2017 | $25,410,000 | -19.4% | 185,000 | -38.3% | 0.44% | -20.7% |
| Q2 2017 | $31,516,000 | +38.7% | 300,000 | +20.0% | 0.55% | +9.3% |
| Q1 2017 | $22,725,000 | -29.5% | 250,000 | -52.2% | 0.50% | -29.6% |
| Q4 2016 | $32,240,000 | +9.3% | 522,536 | +20.1% | 0.72% | +22.6% |
| Q3 2016 | $29,484,000 | +23.8% | 435,000 | -20.9% | 0.58% | +18.9% |
| Q2 2016 | $23,810,000 | +12.0% | 550,000 | +10.0% | 0.49% | +18.3% |
| Q1 2016 | $21,250,000 | -19.3% | 500,000 | +22.0% | 0.42% | -16.0% |
| Q4 2015 | $26,330,000 | -15.7% | 410,000 | +12.3% | 0.49% | -29.2% |
| Q3 2015 | $31,226,000 | -7.3% | 365,000 | +82.5% | 0.70% | -51.8% |
| Q2 2015 | $33,674,000 | -20.3% | 200,000 | -42.9% | 1.45% | -25.8% |
| Q1 2015 | $42,270,000 | +22.9% | 350,000 | -6.7% | 1.95% | +61.9% |
| Q4 2014 | $34,395,000 | +283.4% | 375,000 | +50.0% | 1.21% | +265.8% |
| Q3 2014 | $8,970,000 | -7.0% | 250,000 | 0.0% | 0.33% | -15.4% |
| Q2 2014 | $9,643,000 | +182.7% | 250,000 | +66.7% | 0.39% | +217.1% |
| Q1 2014 | $3,411,000 | +8.4% | 150,000 | 0.0% | 0.12% | +8.8% |
| Q4 2013 | $3,147,000 | -22.2% | 150,000 | 0.0% | 0.11% | -14.4% |
| Q3 2013 | $4,044,000 | – | 150,000 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 4,282,827 | $13,019,794 | 1.84% |
| Birchview Capital, LP | 455,200 | $1,383,808 | 1.18% |
| PFM Health Sciences, LP | 6,040,934 | $18,364,439 | 0.86% |
| Lion Point Capital, LP | 531,256 | $1,615,018 | 0.72% |
| Endurant Capital Management LP | 251,785 | $765,426 | 0.69% |
| Bleichroeder LP | 900,000 | $2,736,000 | 0.67% |
| Connacht Asset Management LP | 31,634 | $96,167 | 0.57% |
| Granahan Investment Management | 5,137,778 | $15,618,845 | 0.56% |
| Frazier Life Sciences Management, L.P. | 1,709,907 | $5,198,117 | 0.34% |
| Contrarius Investment Management Ltd | 1,308,002 | $3,976 | 0.22% |